INDIGO Home University of Illinois at Urbana-Champaign logo uic building uic pavilion uic student center

Going Past the Data for Temozolomide

Show full item record

Bookmark or cite this item: http://hdl.handle.net/10027/8388

Files in this item

File Description Format
PDF Temozolomide Comment.pdf (61KB) (no description provided) PDF
Title: Going Past the Data for Temozolomide
Author(s): Villano, J. Lee; Letarte, Nathalie; Bressler, Linda R.
Subject(s): Glioblastoma Temozolomide Adjuvant therapy Brain tumor
Abstract: The benefit of six cycles of adjuvant temozolomide was documented in a randomized phase III (EORTC‐NCIC CE.3) trial and this therapy, following combined temozolomide and radiation, is the standard of care for patients with newly diagnosed glioblastoma. We comment on the differences on length of adjuvant therapy in both clinical practice and national studies (e.g. RTOG 0825), usually doubling the length than in the EORTC/NCIC study, and relate to historic adjuvant trials for solid tumors.
Issue Date: 2012-04
Publisher: Springer Verlag
Citation Info: Villano, J. L., Letarte, N., & Bressler, L. R. 2012. Going past the data for temozolomide. Cancer Chemotherapy and Pharmacology, 69(4):1113-1115. DOI: 10.1007/s00280-011-1796-4
Type: Article
Description: © 2012 by Springer Verlag, Cancer Chemotherapy and Pharmacology The original publication is available at www.springerlink.com DOI: 10.1007/s00280-011-1796-4
URI: http://hdl.handle.net/10027/8388
ISSN: 0344-5704
Date Available in INDIGO: 2012-06-27
 

This item appears in the following Collection(s)

Show full item record

Statistics

Country Code Views
United States of America 152
China 56
United Kingdom 17
Germany 8
Netherlands 4

Browse

My Account

Information

Access Key